Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Petrelli

Showing results (301-310 of 304) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 304 results.
Cancer Treatment and Research Communications|February 18, 2026
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialChiara Mattioli, Emanuela Olmetto, Marco Banini, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Scientific Reports|December 23, 2015
Natural History of Non-Small-Cell Lung Cancer with Bone MetastasesDaniele Santini, Santini Daniele, Sandro Barni, et al.
Pageof 31

Showing results (301-310 of 304) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 304 results.
Cancer Treatment and Research Communications|February 18, 2026
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialChiara Mattioli, Emanuela Olmetto, Marco Banini, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Scientific Reports|December 23, 2015
Natural History of Non-Small-Cell Lung Cancer with Bone MetastasesDaniele Santini, Santini Daniele, Sandro Barni, et al.
Pageof 31